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ARTICLE
Molecular stratification of endometrioid ovarian
carcinoma predicts clinical outcome
Robert L. Hollis 1,5, John P. Thomson1,5, Barbara Stanley1,5, Michael Churchman1, Alison M. Meynert2,
Tzyvia Rye1, Clare Bartos1, Yasushi Iida1,3, Ian Croy1, Melanie Mackean4, Fiona Nussey4, Aikou Okamoto3,
Colin A. Semple 2, Charlie Gourley 1,6 & C. Simon Herrington 1,6✉
Endometrioid ovarian carcinoma (EnOC) demonstrates substantial clinical and molecular
heterogeneity. Here, we report whole exome sequencing of 112 EnOC cases following rig-
orous pathological assessment. We detect a high frequency of mutation in CTNNB1 (43%),
PIK3CA (43%), ARID1A (36%), PTEN (29%), KRAS (26%), TP53 (26%) and SOX8 (19%), a
recurrently-mutated gene previously unreported in EnOC. POLE and mismatch repair protein-
encoding genes were mutated at lower frequency (6%, 18%) with significant co-occurrence.
A molecular taxonomy is constructed, identifying clinically distinct EnOC subtypes: cases
with TP53 mutation demonstrate greater genomic complexity, are commonly FIGO stage III/
IV at diagnosis (48%), are frequently incompletely debulked (44%) and demonstrate inferior
survival; conversely, cases with CTNNB1 mutation, which is mutually exclusive with TP53
mutation, demonstrate low genomic complexity and excellent clinical outcome, and are
predominantly stage I/II at diagnosis (89%) and completely resected (87%). Moreover, we
identify the WNT, MAPK/RAS and PI3K pathways as good candidate targets for molecular
therapeutics in EnOC.
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Ovarian carcinomas (OC) are a heterogeneous group ofmalignancies comprising five core histological types, eachwith distinct pathological characteristics, molecular
landscapes and clinical behaviour1,2. Endometrioid OC (EnOC)
accounts for approximately 10% of all OC, with the majority of
cases diagnosed as low grade, early stage disease with excellent
clinical outcome3–5.
Currently, the management of EnOC follows the historic one-
size-fits-all approach of aggressive cytoreductive surgery with
adjuvant platinum–taxane chemotherapy for patients with disease
that has progressed beyond the ovary/fallopian tube. By contrast,
routine molecular stratification of care is emerging in other OC
types, most notably with the advent of poly(adenosine dipho-
sphate-ribose) polymerase (PARP) inhibitor therapy6,7.
Targeted sequencing approaches have identified PTEN,
ARID1A, PIK3CA, KRAS, CTNNB1, and genes encoding mis-
match repair (MMR) proteins as frequently mutated in relatively
small cohorts of EnOC8–10, reminiscent of endometrioid endo-
metrial carcinoma (EnEC)11, with a TP53 mutation (TP53m) rate
markedly lower than their high grade serous OC (HGSOC)
counterparts12. Recent whole genome sequencing of a small
EnOC case series has recapitulated these findings and identified a
small proportion of EnOC with extensive copy number altera-
tions (CNAs) more akin to the genomic instability demonstrated
by HGSOC13.
The majority of EnOC are believed to arise from endome-
triosis1, and most grade 1 and 2 (low grade) EnOC display a
classical immunohistochemical (IHC) profile comprising Wilms’
tumour 1 (WT1) negativity, wild-type tumour protein p53 (p53)
expression, and oestrogen receptor (ER) positivity4. These clas-
sical low grade EnOC bear close histological resemblance to
EnEC14.
Grade 3 (high grade) EnOC can be challenging to differentiate
from HGSOC on the basis of morphology alone4,14. In particular,
HGSOC demonstrating the solid, pseudo-endometrioid and/or
transitional-cell-like (SET) histological pattern, which may be
associated with BRCA1 mutations15, represent a population easily
misclassified as EnOC. Indeed, it is now recognised that many
historically diagnosed high grade EnOC in fact represent
HGSOC, supported by transcriptomic studies demonstrating that
a proportion of high grade EnOC cluster with HGSOC16–19. As
such, true high grade EnOC are increasingly rare, representing
only around 5–19 % of EnOC cases4,9,20,21; these patients
reportedly experience poor clinical outcome, in contrast to their
low grade counterparts3,21.
To date, the overwhelming body of clinical and molecular
EnOC characterisation has been confounded by the inclusion of
historically misclassified HGSOC. Mutational analyses performed
by more recent studies have either been applied to low grade
EnOC alone22, or lack information on grade or diagnostic criteria
used8,23 and have ubiquitously analysed small patient cohorts
with insufficient power to confidently correlate molecular events
with patient outcome. As a result, the molecular landscape of
EnOC, in particular high grade EnOC, is poorly defined.
WT1 IHC is a useful tool to discriminate high grade EnOC
(WT1 negative) from HGSOC (WT1 positive), reducing inter-
observer variation16,20,24–27. Here, we perform molecular char-
acterisation of contemporarily defined EnOC with the use of IHC
for WT1. We perform whole exome sequencing (WES) to define
the genomic landscape of EnOC, including high grade EnOC, in a
sizeable cohort of otherwise unselected patients. We identify
subtypes of EnOC that display distinct clinical behaviour, con-
structing a step-wise taxonomy for EnOC classification based on
mutation status of TP53 and CTNNB1. TP53m cases, char-
acterised by greater genomic complexity and frequent CNA
events, demonstrate poor survival; conversely, cases with
CTNNB1 mutation (CTNNB1m)—which occurs mutually exclu-
sively with TP53m—are of low genomic complexity with few
CNA events and demonstrate excellent long-term survival. The
remaining cases represent a subtype with intermediate prognosis.
Results
Clinical characteristics. Of 289 historically diagnosed EnOC
cases identified with available tumour material, 112 WT1 negative
cases were characterised by WES following rigorous pathology
review (Fig. 1). The clinicopathological characteristics of these
patients are shown in Table 1. The majority of patients presented
with stage I or II disease (78.2%, 86 of 110 evaluable cases; 2
unknown stage); 27 stage I/II cases received no adjuvant che-
motherapy. Nineteen cases (17.0%) had concurrent endometrial
cancer diagnosis. The median follow-up time was 13.0 years.
Five-year disease-specific survival (DSS) and progression-free
survival (PFS) across the cohort was 72.8% (95% CI 64.8–81.8%)
and 68.5% (95% CI 60.2–77.9%).
Genomic landscape of endometrioid ovarian carcinoma. The
most commonly mutated genes included CTNNB1 (48 cases,
42.9%), PIK3CA (48 cases, 42.9%), ARID1A (40 cases, 35.7%),
PTEN (33 cases, 29.5%), KRAS (29 cases, 25.9%), and TP53 (29
cases, 25.9%) (Supplementary Fig. 1). Unsupervised hierarchical
clustering across the 50 most commonly mutated genes revealed
mutation of TP53 and CTNNB1 (TP53m and CTNNB1m) as the
most prominent stratifying events (Fig. 2 and Supplementary
505 Patients
216 No tumour available
28 Patients
17 Non-evaluable tumour
1 Non-evaluable WT1 stain
6 Endometrial primary
1 Ovarian metastasis
1 Colorectal cancer metastasis 
(confirmed CK7
negative/CK20 positive)
2 Concurrent metastatic
malignancy
120 WT1 positive patients
109 High-grade serous
3 Mixed histology
2 Borderline serous
6 WT1 positive grade I/II cases 
of endometrioid histology
14 Patients
6 Clear cell carcinoma
6 Mixed histology 
1 Carcinosarcoma
1 Mucinous carcinoma
15 Patients
4 Insufficient material for DNA 
extraction 
8 Failed DNA QC
3 Failed sequence QC (mean 
coverage <30×)112 WT1 negative
cases with WES
289 patients for
review and IHC 
69 Grade 1 EnOC
17 Grade 2 EnOC
8 Grade 3 EnOC
3 WT1 negative undifferentiated cases
15 WT1 negative cases with serous features
Fig. 1 Flow diagram identifying endometrioid ovarian carcinoma cases for
whole exome sequencing. IHC immunohistochemistry, WES whole exome
sequencing, EnOC endometrioid ovarian carcinoma, WT1 Wilms’ tumour 1,
QC quality control.
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Fig. 2). TP53m and CTNNB1m were largely mutually exclusive
(Fig. 3a), with significant depletion of CTNNB1m in the TP53m
group (P < 0.001; co-occurrence in one case, 0.9%). The
CTNNB1m rate in the TP53 wild-type (TP53wt) group was 56.6%
(47 of 83 TP53wt cases).
Mutation of SOX8, a gene target of mutational disruption
previously unreported at high frequency in EnOC, was also
identified as a common event (21 cases, 18.8%), alongside other
targets of mutation (Fig. 3a and Supplementary Figs. 1, 3A).
There was significant enrichment of SOX8m in the TP53m group
(10/29, 34.5% SOX8m in the TP53m group vs. 11/83, 13.3%
SOX8m in the TP53wt group; P= 0.025). Events in other genes
previously reported as mutated in EnOC or endometrial cancer
were identified at lower frequency, including FBXW7m (14 cases,
12.5%), KMT2D/MLL3m (12 cases, 10.7%), BRCA1/2m (14 cases,
12.5%) (Supplementary Table 1), PIK3R1m (10 cases, 8.9%),
MTORm (7 cases, 6.3%), POLEm (7 cases, 6.3%) (Supplementary
Fig. 3B), APC (6 cases, 5.4%) and PPP2R1Am (4 cases, 3.6%)
(Fig. 3a and Supplementary Fig. 1). BRCA1/2m cases demon-
strated a high rate of TP53m (57.1%, 8 of 14 cases) and a high rate
of mutation in genes previously reported in EnOC (71.4%, 10 of
14 cases with mutations in ARID1A, CTNNB1, PTEN, PIK3CA,
KRAS, or genes encoding mismatch repair proteins).
Pathway analysis identified a large number of mutations across
four major oncogenic pathways: PI3K-AKT, WNT, RAS, and
NOTCH (Supplementary Fig. 4).
Tumour mutational burden (TMB) and microsatellite
instability (MSI). A median of 78 variants were detected per
sample (range 42–2894) (Supplementary Figs. 5, 6A). Ten cases
(8.9%) were considered hypermutated (>250 mutations per
sample) and 3 (2.7%) were considered ultramutated (>1000
mutations) (Fig. 3a). Overall analysis of TMB against TCGA
derived datasets places EnOC alongside HGSOC (median TMB
= 72), colonic adenocarcinoma (median TMB= 76) and EnEC
(median TMB= 78) (Supplementary Fig. 6B).
Mutations in one or more genes encoding MMR proteins were
identified in 20 cases (17.9%) (Fig. 3c), most commonly inMSH3,
MSH6,MLH3 orMSH4. The majority of MMR-mutant (MMRm)
tumours were TP53wt (18/20 cases, 90.0%). High impact MMRm
(frameshifting InDels, nonsense or splice site mutations) were
associated with significantly higher MSI scores compared to those
containing missense MMRm (median 236 vs. 142.5, P < 0.001)
and MMRwt samples (median 236 vs. 162, P < 0.001) (Fig. 3a and
Supplementary Fig. 7). There was no significant difference in MSI
score between MMRwt cases and those with missense MMRm
(P= 0.194).
POLEm commonly occured over a hotspot within the
exonuclease domain (42.9%, 3 of 7 POLEm cases) (Supplemen-
tary Fig. 3B). There was a high frequency of concurrent POLEm
and MMRm (five of seven POLEm cases, 71.4%), with significant
enrichment for MMRm within the POLEm versus POLEwt group
Table 1 Clinical characteristics of the 112 endometrioid
ovarian carcinoma cases.
N/median %/range
Cases 112
Age (years) 58.5 28–88
BMI (kg per square metre height) 25.4 18.0–44.0
Concurrent endometrial cancera 19 17.0
Endometrioisisb 39 34.8
Grade
Grade 1 EnOC 69 61.6
Grade 2 EnOC 17 15.2
Grade 3 EnOC 8 7.1
Undifferentiated 3 2.7
Serous-like features 15 13.4
Vital status at last follow-up
Deceased, ovarian cancer 35 31.3
Deceased, other causes 19 17.0
Alive 58 51.8
Period of diagnosis
1980s 17 15.2
1990s 44 39.3
2000s 32 28.6
2010s 19 17.0
FIGO stage at diagnosis
I 47 42.7
II 39 35.5
III 15 13.6
IV 9 8.2
NA 2 –
Primary debulking status
Zero macroscopic RD 82 78.1
Macroscopic RD 23 21.9
NA 7 –
Adjuvant chemotherapy stage I/II (n= 86)
Single-agent platinum 31 36.5
Platinum–taxane combination 17 20.0
Other platinum combination 3 3.5
Other chemotherapy regime 7 8.2
No adjuvant chemotherapy 27 31.8
NA 1 –
Adjuvant therapy stage III/IV (n= 24)
Single-agent platinum 14 58.3
Platinum–taxane combination 2 8.3
Other platinum combination 2 8.3
Other chemotherapy regime 1 4.2
No adjuvant chemotherapy 5 20.8
BMI body mass index, EnOC endometrioid ovarian carcinoma, NA not available, RD residual
disease, FIGO International Federation of Obstetrics and Gynecology.
aDocumented on the Edinburgh Ovarian Cancer Database.
bDocumented on the diagnostic pathology report or identified from reviewed archival tissue.
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Fig. 2 Unsupervised clustering of endometrioid ovarian carcinomas by
patterns of mutation. Product-moment correlation scores between
samples were calculated using binary matrices representing the status of
most frequently mutated genes (1=mutant, 0=wild-type), yielding a
matrix of quantified genomic correlation. These data were subject to
hierarchical clustering using Euclidean distance and Ward’s linkage. Bars
denote mutation in CTNNB1 and TP53.
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(71.4%, 5/7 vs. 14.3%, 15/105, P= 0.002). Together, the POLEm
and high impact MMRm cases accounted for the majority of high
TMB cases (Fig. 3d). Cases with concurrent POLEm and MMRm
accounted for all three ultramutated tumours; 8 of the 10 (80.0%)
hypermutated tumours contained either POLEm or high
impact MMRm.
Mutational spectrum in endometrioid ovarian carcinoma. We
observed a bias towards C>T and C>A transversion and transi-
tion molecular signatures across the 112 EnOC cases (Fig. 3a). A
shift in signatures was observed in samples harbouring POLEm,
with a greater proportion of T>G changes, and depletion of C>G
and T>A substitutions in this population (Supplementary Fig. 8).
Tumour genomic complexity and copy number alterations.
Distribution of per-sample global variant allele frequency (VAF)
density and calculation of mutant-allele tumour heterogeneity
(MATH) score across the 112 EnOC cases was used to infer
tumour genomic complexity (Fig. 4). TP53wt tumours were
predominantly low complexity, demonstrating lower MATH
scores (median 27.5 vs. 54.7, P < 0.001) (Fig. 4b, c and Supple-
mentary Fig. 9A) and fewer discrete VAF peaks (P < 0.001)
(Supplementary Table 2) compared to TP53m cases.
Analysis of CNA events across samples revealed differential
CNA burden across molecular subgroups defined by TP53m and
CTNNB1m status, with TP53m cases harbouring greater CNA
burden compared to TP53wt tumours (P < 0.0001) (Supplemen-
tary Figs. 9B, 10A, B). The most frequent CNA events across the
cohort were gain of ZNF43 (30 cases, 26.8%), RABA1C (24 cases,
21.4%) and AMY1C (23 cases, 20.5%), and loss of PKNOX1 (42
cases, 37.5%), CEP68 (29 cases, 25.9%) and GLB1L (20 cases,
17.9%) (Supplementary Fig. 10C). CNA events were also
identified over genes that were frequent targets of mutational
disruption (Supplementary Fig. 10D).
Molecular events define clinically distinct disease subtypes.
TP53m cases demonstrated significantly inferior DSS upon uni-
variable analysis (HR= 4.43, 95% CI 2.27–8.64, Bonferroni-
adjusted P < 0.001) (Supplementary Figs. 11A, 12A and Supple-
mentary Table 3), were more likely to be diagnosed at advanced
stage (14 of 29 evaluable cases, 48.3% stage III/IV vs. 10 of 81,
12.3%; P < 0.001) (Supplementary Table 4), less likely to be suc-
cessfully resected to zero macroscopic residual disease (RD)
(44.4%, 12 of 27 evaluable cases with macroscopic RD after
surgical debulking vs. 14.1%, 11 of 78; P= 0.003), and demon-
strated a trend for greater age at diagnosis which did not meet
statistical significance (median 61 vs. 57 years, P= 0.063). Mul-
tivariable analysis accounting for patient age, stage at diagnosis,
and extent of RD following primary cytoreduction identified
TP53m as independently associated with shorter DSS (P= 0.031)
(Supplementary Tables 5, 6). The TP53m group demonstrated
significant depletion of cases with concurrent endometrial cancer
diagnosis (3.4%, 1 of 29 TP53m vs. 21.7%, 18 of 83 TP53wt,
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P= 0.023). The median DSS and PFS for TP53m cases were 3.78
and 1.54 years, respectively.
By contrast, cases with CTNNB1m were overwhelmingly stage
I/II at diagnosis (89.1%, 41 of 46 evaluable cases) and debulked to
zero macroscopic RD (87.0%, 42 of 46 evaluable cases), with
markedly favourable outcome (HR for DSS= 0.23, 95% CI
0.10–0.56, Bonferroni-adjusted P= 0.010) (Supplementary
Figs. 11B, 12B and Supplementary Table 3) which was significant
upon multivariable analysis (P= 0.017) (Supplementary Tables 7,
8). CTNNB1m was significantly associated with favourable
outcome specifically in the context of TP53wt cases (HR for
DSS= 0.31, 95% CI 0.11–0.88) (Fig. 5a), and TP53wt/CTNNB1m
cases were less genomically complex vs. their TP53wt/CTNNB1wt
counterparts (median MATH score 26.3 vs. 31.9, P= 0.035) with
fewer CNA events (P= 0.042) (Fig. 4c and Supplementary
Fig. 10B). The DSS difference between genomic subgroups defined
by combined TP53m and CTNNB1m status was maintained upon
exclusion of cases with concurrent endometrial carcinoma (P <
0.001) (Supplementary Fig. 13) and upon exclusion of cases
demonstrating TP53m in the absence of endometrioid-associated
mutations (P < 0.001) (Supplementary Fig. 14).
POLEm EnOC cases did not demonstrate an obvious
exceptional 5-year survival pattern akin to that reported in
POLEm endometrial carcinomas, and did not demonstrate
prolonged DSS vs. POLEwt patients (5-year DSS 85.7%; P=
0.337 vs. POLEwt) (Supplementary Table 3), although case
numbers were extremely low (n= 7).
Greater tumour complexity was associated with inferior
survival when defined by the number of VAF peaks (P= 0.020
for DSS) or continuous MATH score (P < 0.001 for DSS)
(Supplementary Table 9). Exploratory analysis to determine
whether the outcome of TP53wt/CTNNB1wt cases could be
further resolved by genomic complexity identified that low
complexity TP53wt/CTNNB1wt cases (MATH score ≤ median
MATH score in EnOCs with a single VAF peak) demonstrated
relatively favourable outcome (10-year DSS 77.0%) (Supplemen-
tary Fig. 15), while their more genomically complex counterparts
demonstrated intermediate prognosis (10-year DSS 48.7%);
however, this difference did not reach statistical significance
and case numbers were limited.
Together, these data support a clinically meaningful classifica-
tion system driven TP53m and CTNNB1m status in a step-wise
b PRISTINE algorithm: PRognostic GenomIc StratificaTIoN of EnOC
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fashion, which we present here as the PRISTINE algorithm:
PRognostic genomIc StratificaTIoN of EnOC (Fig. 5b). Genomic
complexity may represent a potential tool to further discriminate
outcome in these subtypes.
Utility of immunohistochemistry to identify disease subtypes.
IHC for p53 and β-catenin, the protein products of TP53 and
CTNNB1, was able to identify subgroups of EnOC with differ-
ential DSS (P < 0.001 and P= 0.045) (Supplementary Fig. 16A,
B). Combined use of these markers to recapitulate the PRISTINE
algorithm identified patient groups with differential DSS akin to
those defined by genomic data (P < 0.001) (Supplementary
Fig. 16C). However, aberrant β-catenin expression (βcat-aber-
rant) resolved outcome less well in those with wild-type p53
protein expression (p53-wt) compared to CTNNB1m status in the
TP53wt group (Fig. 5a), likely owing to the suboptimal sensitivity
of β-catenin IHC for CTNNB1m (Supplementary Fig. 16B).
Discussion
The molecular landscape of EnOC is poorly defined, particularly
in high grade cases, due to under-investigation and historic
misclassification of HGSOC as high grade EnOC in older studies.
WT1 negativity has emerged as an important discriminator of
high grade EnOC from HGSOC, which displays morphological
similarities4,24–27. To our knowledge, this is the largest report of
genomically characterised EnOC to date, utilising routine WT1
IHC to exclude pseudo-endometrioid HGSOC that have con-
taminated previous studies of this cancer type.
In line with previous sequencing studies in small cohorts of
EnOC, we identified a high mutation rate of genes known to be
perturbed in EnEC, the most frequent of which were CTNNB1,
PIK3CA, PTEN, ARID1A, KRAS, and TP538,11,22,28,29. Our EnOC
cohort demonstrated a similar rate of TP53m to the TCGA study
of EnEC11; by contrast, the mutation rate of PTEN was lower. We
demonstrate that EnOC tumours contain a moderate TMB with
respect to other cancer types, with a small proportion hyper-
mutated or ultra-mutated in nature (11.6%).
MMR deficiency due to mutations or methylation in MMR
protein-encoding genes results in MSI, and loss of MMR protein
expression has previously been demonstrated in approximately
7–14% of EnOC30–34. As in EnEC, we identify a subgroup of
EnOC harbouring MMRm, with a similar overall MMRm rate as
reported previously in EnOC30–34. We demonstrate that cases
with high impact MMRm (nonsense, frameshifting or splice site
mutations) demonstrate MSI and that these cases account for
many of the samples demonstrating high TMB. POLEm was rare
in this cohort (6.3% of cases); there was significant enrichment for
MMRm within this population (P= 0.002) and concurrent
mutation of POLE and MMR genes was present in all three
ultramutated tumours. Notably, when considering only missense
MMRm, we observed no significant difference in MSI score
compared to MMRwt cases, suggesting fewer missense mutations
lead to functional loss of MMR. Moreover, POLEm cases did not
appear to demonstrate the exceptional 5-year survival reported in
POLEm endometrial carcinomas11, and was not associated with
significantly prolonged survival, though the power of this analysis
was severely limited. The low POLEm rate we observed is con-
sistent with previous reports in EnOC35,36.
Collectively, the data presented here identify TP53m EnOC as a
distinct clinical and biological subtype of disease. TP53m cases
demonstrated higher levels of CNA events, greater tumour
genomic complexity, higher rate of advanced stage at diagnosis,
inferior rate of complete macroscopic tumour resection, and
overall poor clinical outcome. This is consistent with the poor
prognosis reported in EnEC harbouring TP53m11, is reminiscent
of HGSOC12, and is in line with several studies of EnOC28,37. In
particular, the study performed by Parra-Herran et al.28 applied
the PROMISE algorithm, an EnEC molecular classifier, to a
cohort of WT1 negative EnOC and found the p53-aberrant group
to have the worst survival; a recent study of early stage EnOC also
reported poor outcome for cases with p53-aberrant cases38. In
our cohort, TP53m cases also represented those least likely to
demonstrate concurrent endometrial cancer.
While the copy number and survival profile of our TP53m
EnOC group provides one rationale for reclassification of these
tumours as HGSOC, the high frequency (48.3%, 14 of 29) of
classic EnOC mutations (CTNNB1, PTEN, ARID1A, KRAS,
PIK3CA, or MMRm), lack of WT1 expression (in all cases) and
high rate of early stage diagnosis in this cohort (51.7%, 15 stage
I/II) form a compelling argument that these represent true
EnOC. Indeed, these poorer prognosis EnOC cases may well be
suitable for inclusion alongside true HGSOC in trials of novel
therapeutic strategies for aggressive OC types. Only nine cases
(8.0% of our cohort) represented feasible candidates as possible
true WT1-negative HGSOC (advanced stage at diagnosis and
TP53m without mutations suggestive of endometrioid carcinoma
i.e., MMR, PTEN, CTNNB1, PIK3CA, ARID1A and KRAS wild-
type), which are recognised as a rare phenomenon (≤5% HGSOC
cases)24. The true histological subtype of this small group cannot
be determined with absolute certainty; however, sensitivity
analysis excluding possible occult serous carcinomas of ovarian
or endometrial origin identified the same outcome differences
between genomic subtypes.
Conversely, CTNNB1m—which appears mutually exclusive
with TP53m—is associated with early-stage disease of low geno-
mic complexity that is easily debulked to zero macroscopic RD,
and these cases demonstrate excellent clinical outcome. This is in
contrast to findings in EnEC associating CTNNB1m with a
greater chance of recurrence39. Within our EnOC cohort,
CTNNB1m status was also associated with favourable outcome
specifically in the context of TP53wt tumours, suggesting clinical
impact independent of its anti-correlation with TP53m. These
data support the notion of a tiered classification system driven by
TP53m and CTNNB1m status to define molecular subtypes of
EnOC with markedly differential clinical outcome and clin-
icopathological features; this classifier—the PRISTINE algorithm
—should now be validated in an independently curated, suffi-
ciently powered EnOC dataset defined using contemporary cri-
teria, including the use of WT1 IHC. We demonstrate that
consideration of genomic complexity may provide a potential
future way to further resolve outcomes within these subgroups,
though this analysis was exploratory in nature.
Despite the variability in processing, age, fixation and pre-
servation of tissue specimens, we demonstrate that IHC for p53
and β-catenin proteins can recapitulate this classification system,
but is limited by the sensitivity of β-catenin IHC for detecting
CTNNB1m, consistent with previous reports of β-catenin
immunostaining as a surrogate for CTNNB1m40,41. Imple-
mentation of IHC-based classification may well demonstrate
improved sensitivity/specificity in newly diagnosed cases with
uniformly fixed, well preserved whole-slide tissue sections.
The high rate of genomic disruption in CTNNB1, KRAS, PTEN
and PIK3CA suggests that inhibitors of the WNT, MAPK and
PI3K pathways represent agents with potential clinical utility in
EnOC treatment. Efforts to identify novel therapeutic strategies
should focus on cases with greatest unmet clinical need, namely
CTNNB1wt cases. In particular, TP53m cases represent those
where further treatment options are urgently required to improve
outcome, and we identified potentially clinically actionable
mutations in a large proportion of these cases (14% with KRASm,
28% with PTENm/PIK3CAm, 28% with BRCA1/2m).
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Finally, we identify SOX8 as a gene target of recurrent mutation
in EnOC. SRY-related high mobility group box (SOX) genes
encode a family of transcription factors, which act as critical
regulators of cellular programming and are frequently altered in
many cancers42. Interestingly, analysis of TCGA data reveals that
SOX8m occurs at low frequency in uterine cancers (3% in uterine
corpus endometrial carcinoma, 1% in uterine carcinosarcoma) as
well as in colonic adenocarcinoma (2%) (data from the TCGA
portal43). As recent studies suggest that SOX8 in part regulates
the activity of genes associated with the WNT/β-catenin pathway,
a commonly mutated pathway in EnOC, mutation of this gene
may impact on classically defined EnOC pathways through this
route44. Genomic disruption of SOX8 therefore represents a
previously unreported candidate mechanism by which EnOC
may frequently perturb the WNT/β-catenin pathway. Given the
frequent co-occurrence of SOX8m and TP53m in our cohort
(34.5% SOX8m in the TP53m group), selection bias against true
high grade EnOC in previous studies—leading to depletion of
TP53m cases in those cohorts—may explain why SOX8m has not
previously been identified as a common genomic event in EnOC.
Beyond genomic characterisation, a transcriptomic study of
EnOC identified clinically meaningful patient subgroups defined
at the gene expression level akin to those previously described in
HGSOC18. Interestingly, while the poorer prognosis of genomi-
cally complex EnOC cases we describe here might be expected to
produce a more pronounced anti-tumour immune response, the
immunoreactive transcriptomic subgroup they identified did not
demonstrate the poorest outcome. Future work should seek to
correlate EnOC subgroups defined at these different levels in
order to determine the association between genomic and tran-
scriptomic events in this tumour type. Similarly, comparison with
subgroups defined at the proteomic level, including those based
on expression patterns of hormone receptors45, should be made.
In summary, we have demonstrated that EnOC is a molecularly
heterogeneous disease, comprising multiple genomic subtypes.
These subtypes demonstrate differential clinical outcome and
clinicopathological features. In particular, our study highlights
CTNNB1m and TP53m as markers of biologically distinct sub-
types of EnOC with contrasting clinical behaviour. These markers
have the potential to inform future prognostication and molecular
stratification within EnOC. Gene sequencing of TP53 and
CTNNB1, or IHC directed at their respective gene products,
represent mechanisms by which these findings could readily be
translated into routine risk-stratification of newly diagnosed
cases. Patients with EnOC demonstrating absence of CTNNB1m
and/or presence of TP53m have the greatest unmet clinical need;
many of these tumours harbour activating mutations in pathways
that may be targetable with molecular agents. Investigating the
clinical efficacy of inhibitors of the MAPK/RAS, WNT and PI3K
pathways has the potential to identify agents that will improve
EnOC patient survival.
Methods
Ethical approval. Ethical approval for the use of human tissue specimens for
research was obtained from South East Scotland Scottish Academic Health Sciences
Collaboration BioResource (reference 15/ES/0094-SR494). Correlation of mole-
cular data to clinical outcome and clinicopathological variables in ovarian cancer
was approved by NHS Lothian Research and Development (reference 2007/W/ON/
29). All relevant ethical regulations have been complied with, including the need
for written informed consent where required.
Pathology review and immunohistochemistry. 505 patients diagnosed with OC
between August 1968 and May 2014, and whose pathology reports contained the
term “endometrioid”, were identified through the Edinburgh Ovarian Cancer
Database (Fig. 1); tumour material was available for 289 cases45. Chemotherapy
naïve tumour from the primary site was selected where available. Pathology review
was conducted as per WHO 2014 classification, including IHC for WT1 in every
case (see Supplementary Methods), by an expert gynaecological pathologist (CSH).
A confirmatory observer (BS) was present for all pathology review. The presence of
endometriosis was recorded from the reviewed slides or pathology report.
Cases with non-interpretable morphology, non-evaluable tumour and cases
representing metastases from primary endometrial cancer, as defined by WHO
criteria, were excluded. Ovarian metastases, WT1 positive tumours,
carcinosarcomas and carcinomas of clear cell, mucinous or mixed histology were
also excluded (Fig. 1). IHC for cytokeratin 7 and cytokeratin 20 (CK7 and CK20)
was performed to exclude colorectal adenocarcinoma metastases
(see Supplementary Methods). p53 and β-catenin IHC was performed as described
in the Supplementary Methods.
Clinical data. Baseline characteristics and outcome data were extracted from the
Edinburgh Ovarian Cancer Database, wherein the diagnostic, treatment and
follow-up data for every ovarian cancer patient treated at the Edinburgh Cancer
Centre is prospectively entered as a part of routine care5. DSS was calculated from
the date of pathologically confirmed OC diagnosis. PFS was recorded as the
duration between the date of diagnosis to the date of first radiological progression
or recurrence, or death from EnOC.
DNA extraction. H&E-stained slides were marked by an expert gynaecological
pathologist (CSH) to identify tumour areas suitable for macrodissection in order to
enrich for tumour cellularity. DNA extraction was performed using the QIAamp
DNA formalin-fixed paraffin-embedded (FFPE) Tissue Kit (Qiagen, Venlo,
Netherlands) and Deparaffinization Solution according to the manufacturer’s
instructions.
Whole exome sequencing. Exome capture was performed using the Illumina
TruSeq Exome Library Prep kit (see Supplementary Methods) and WES was
performed on the Illumina NextSeq 550 (Illumina, Inc., San Diego, CA, USA). The
median per-sample on-target coverage in the successfully sequenced samples was
89.5× (range 36×–289×). Data were aligned to the GRCh38 human reference
genome using bwa-0.7.1746, duplicates marked and base quality scores recalibrated
with the GenomeAnalysisToolkit (GATK) v447 in the bcbio pipeline (see Supple-
mentary Methods).
Variant calling and classification. Variant calling was performed using a majority
vote system from three variant caller algorithms: VarDict48, Mutect249 and Free-
bayes50. Filtering for FFPE and oxidation artifacts was applied using GATK Col-
lectSequencingArtifactMetrics and FilterByOrientationBias. Variants associated
with low sequence depth (<20×) or low variant allele frequency (<10%) were
removed. Common variants were excluded using the 1000 genomes and ExAC
reference datasets; known pathogenic and benign variants were flagged using
ClinVar51, and remaining variants were filtered to remove likely non-functional
variation using the Polymorphism Phenotyping (PolyPhen)52 and Sorting Intol-
erant from Tolerant53 functional prediction tools (see Supplementary Methods).
MSI score was assessed as the number of short insertions or deletions (InDels)
detected in a given sample. TMB was defined as the number of mutations present
in a given tumour following filtering. TMB across other cancer datasets in The
Cancer Genome Atlas (TCGA) were contrasted against those in our EnOC
datasets54. Transitions and transversions were calculated using the titv function in
maftools55.
Unsupervised analysis was performed using the top 50 most frequently mutated
genes represented as a binary matrix (0, wild-type; 1, mutant). Product-moment
correlation scores were calculated between these binary signatures of each sample
to form a matrix of quantified genomic correlation. Samples were then clustered by
Euclidian distance and Ward’s linkage based on this correlation matrix. Heat maps
were drawn in R using the ggplot package. Supervised mutational analysis was
performed using the most commonly mutated genes across sequenced samples.
Genomic events in these genes and overall TMB analysis were visualised using the
R package maftools55. Pathway analysis was carried out using the
OncogenicPathways function56.
Tumour genomic complexity scoring. Tumour genomic complexity was assessed
by VAF density using the inferHeterogeneity function in the R package
maftools55,57 (see Supplementary Methods). Resulting MATH scores represent the
width of the VAF distribution; specimens of low complexity with a single driver
event and associated outgrowth demonstrate fewer VAF peaks with a lower MATH
score. Conversely, highly complex tumours with multiple driver events, branched
evolution and multiple subclonal populations demonstrate multiple VAF peaks and
higher MATH score.
Copy number alteration detection. Copy number analysis was performed using
GeneCN pipelines in Bio-DB-HTS version 2.10 to identify regions of significant
copy number gain or loss (copy number score >5 standard deviations from
reference, P < 0.05) using the pooled TP53wt samples as a reference population.
Statistical analysis. Statistical analyses were performed using R version 4.0.0.
Comparisons of continuous data were made with the Mann–Whitney U-test or T-
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test, as appropriate. Median follow-up time was calculated using the reverse
Kaplan–Meier method. Survival analysis was performed using Cox proportional
hazards regression models in the Survival package. Multivariable analyses
accounted for FIGO stage, patient age at diagnosis, decade of patient diagnosis and
extent of RD following surgical cytoreduction. Comparisons of frequency were
performed using the Chi-square test or Fisher’s exact test, as appropriate. Cor-
rection for multiplicity of testing was performed using the Bonferroni method
where appropriate.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The primary and processed data used to generate the analyses presented here are
available via the European Genome-phenome Archive (accession EGAS00001004366)
upon request to our data access committee; committee approval is required to comply
with the local research ethics framework. For more information please see [https://ega-
archive.org/access/data-access]. The remaining data are available in the Article,
Supplementary Information or available from the authors upon request. The 1000
Genomes and ExAC reference datasets can be found at [http://www.
internationalgenome.org] (version: phase 1 SNP and InDel) and [http://exac.
broadinstitute.org] (version ExAC.0.3.GRCh38).
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